VVOS
Vivos Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.19
+6.76%Aug 14, 2026, 22:27 UTC
Vivos Therapeutics, Inc. held its Q2 2026 earnings call on August 14, 2026.
Source:Jul 7, 2026, 00:00 UTC
Vivos Therapeutics, Inc. entered into a securities purchase agreement for a PIPE offering of 3,608,496 units at $0.582 per unit, raising approximately $2.1 million, with each unit consisting of one share of Series A Convertible Preferred Stock and a five-year warrant.
Jun 22, 2026, 12:30 UTC
Vivos Therapeutics extended its strategic financing agreement with Streeterville Capital, extending the timeframe to August 31, 2026, and reaffirming conversion of up to $4.5 million of debt into common stock and perpetual preferred equity.
Jun 10, 2026, 13:03 UTC
Vivos Therapeutics entered into a collaboration agreement with South Palm Cardiovascular Associates to form AIM Florida, LLC, expanding sleep apnea and insomnia diagnosis and treatment for cardiovascular patients in Florida.
Jun 8, 2026, 00:00 UTC
Vivos Therapeutics entered into an exchange agreement with Streeterville Capital to convert up to $4.5 million of outstanding secured note principal into equity, with conditions including completing equity financings by June 15, 2026.